Mintz Advises ArriVent Biopharma in $155M Series B Financing
Key Facts
- ArriVent Biopharma, Inc, a Pennsylvania-based company, is dedicated to accelerating the global development of innovative biopharmaceutical therapeutics
- Mintz represented ArriVent in a $155M Series B Financing, which will be used to support Phase 3 and additional studies of the company’s lead product candidate, furmonertinib – a highly brain-penetrant, mutant-specific EGFR kinase inhibitor
Mintz represented ArriVent Biopharma, Inc, a Pennsylvania-based company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, in a $155 Million Series B financing.
Proceeds from the financing will be used to support pivotal Phase 3 and additional studies of ArriVent’s lead product candidate, furmonertinib – a highly brain-penetrant, mutant-specific EGFR kinase inhibitor – as well as the continued expansion of the company’s pipeline.
The financing was led by Sofinnova Investments and General Catalyst, with participation from Catalio Capital Management, HBM Healthcare Investments, Shanghai Healthcare Capital, Sequoia China, AIHC Capital, Terra Magnum Capital Partners, Unicorn Capital Partners Limited, and Infinitum Asset Management.
The Mintz team acting for ArriVent was led by Member Ed C. Pease and Private Equity Co-chair Matthew T. Simpson.
Supporting Professionals
